exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

Published Phase 2 Data Highlight Potential of NNZ-2591 in Phelan-McDermid Syndrome Marco Meglio

A phase 2 trial shows NNZ-2591 improves symptoms in children with Phelan-McDermid syndrome, paving the way for a phase 3 study.

Neuroprotective Agent Privosegtor Gains FDA Breakthrough Designation for Optic Neuritis Marco Meglio

Oculis advances Privosegtor, a potential first neuroprotective therapy for optic neuritis, following FDA breakthrough designation and promising trial results.

This Week on NeurologyLive® — January 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Annexon Submits Marketing Authorization Application for Tanruprubart to Treat Guillain-Barré Syndrome Louie Pasculli

Annexon submitted an EMA marketing application for tanruprubart, a first-in-class C1q monoclonal antibody that showed faster and more complete recovery in Guillain-Barré syndrome patients across randomized trials.

NeurologyLive® Brain Games: January 11, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!

Inside the 2026 MDA Conference: Emerging Research Themes in Neuromuscular Medicine Marco Meglio, Angela Lek, PhD

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

A phase 2 trial shows NNZ-2591 improves symptoms in children with Phelan-McDermid syndrome, paving the way for a phase 3 study.

Oculis advances Privosegtor, a potential first neuroprotective therapy for optic neuritis, following FDA breakthrough designation and promising trial results.

Here's some of what is coming soon to NeurologyLive® this week.

Annexon submitted an EMA marketing application for tanruprubart, a first-in-class C1q monoclonal antibody that showed faster and more complete recovery in Guillain-Barré syndrome patients across randomized trials.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.

News All Time

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Claims Study Highlights Persistence and Reasons for Fenfluramine Use in Lennox-Gastaut Syndrome Marco Meglio

An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.

FDA Action Update, December 2025: Acceptance, Approval, and Clearance Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment Marco Meglio

The newly approved generic product is expected to perform like other high-quality glatiramer acetate generics, with differences confined mainly to the manufacturer and device, not mechanism or dosing.

Semaglutide Linked to Improved Neurological Outcomes in Large Vessel Occlusion Without IV Thrombolysis Marco Meglio

A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.

AI Model Distinguishes EDSS Subgroup Patterns in Multiple Sclerosis, Study Shows Louie Pasculli

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.

This Week on NeurologyLive® — January 5, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Uncovering the Complex Relationship Between ADHD and Epilepsy Surgery Outcomes Marco Meglio

Janelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.

A Clinical Review of the 2025 Neuromyelitis Optica Spectrum Disorder Guidelines Benjamin Greenberg, MD, Louie Pasculli

Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.

NeurologyLive® Brain Games: January 4, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on preventative migraine therapies!

Clinical Perspectives on Promising Phase 1 Data of CAPN2-Targeting Therapy AMX0114 for ALS Marco Meglio

ALS expert Sabrina Paganoni, MD, PhD, provided follow-up commentary on promising phase 1 data from the LUMINA trial testing Amylyx’s novel agent AMX0114 in patients with early-stage ALS.

Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026 Marco Meglio

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care.

Previewing Expected FDA Decisions in Neurology for 2026 Marco Meglio

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care? Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

NeurologyLive® Friday 5 — January 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.

Linking Exercise to Dopamine and Motor Performance in Parkinson Disease Marco Meglio

Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.

Recommended News For You

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Radiotherapy after mastectomy can be avoided, study finds

Preoperative Embolization Linked to Relapse-Free Survival in Meningioma

Recommended Articles For You

PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision 

The Importance of Having a Quick and Effective Heparin Antidote  

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells 

The Lung Cancer Shift: From Reactive Treatment to Proactive Precision Medicine 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.

2.

A paper strip test might enable the early detection of cancer.

3.

Breast cancer patients' arms swell less after an effective lymph node transfer.

4.

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

5.

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

1.

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target

2.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

3.

Seeing the Unseen: Examining Chancroid Through Images

4.

Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology

5.

Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC

2.

Navigating the Complexities of Ph Negative ALL - Part IV

3.

Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot